down arrow

Genomed SA

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLGNOMD00024
PLN
28.00
-0.2 (-0.71%)

Dec 12

WAR

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Genomed SA
Telemedycyna Polska SA
Why is Genomed SA ?
1
With a growth in Net Sales of 25.05%, the company declared Very Positive results in Mar 25
  • OPERATING CASH FLOW(Y) Highest at PLN 2.12 MM
  • ROCE(HY) Highest at 21.32%
  • RAW MATERIAL COST(Y) Fallen by -195.5% (YoY)
2
With ROE of 21.50%, it has a fair valuation with a 3.74 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 10.24%, its profits have risen by 154% ; the PEG ratio of the company is 0.1
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Genomed SA should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Genomed SA for you?

Low Risk, Low Return

Absolute
Risk Adjusted
Volatility
Genomed SA
10.24%
0.00
29.96%
Poland WIG
39.24%
1.84
20.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
7.86%
EBIT Growth (5y)
33.18%
EBIT to Interest (avg)
1.04
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
2.59
Tax Ratio
5.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.90%
ROE (avg)
8.65%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
3.74
EV to EBIT
13.71
EV to EBITDA
10.54
EV to Capital Employed
5.58
EV to Sales
1.36
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
40.69%
ROE (Latest)
21.50%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
OPERATING CASH FLOW(Y)

Highest at PLN 2.12 MM

ROCE(HY)

Highest at 21.32%

RAW MATERIAL COST(Y)

Fallen by -195.5% (YoY

CASH AND EQV(HY)

Highest at PLN 10.03 MM

DEBT-EQUITY RATIO (HY)

Lowest at -47.05 %

INVENTORY TURNOVER RATIO(HY)

Highest at 11.3%

PRE-TAX PROFIT(Q)

At PLN 0.24 MM has Grown at 139.77%

NET PROFIT(Q)

At PLN 0.24 MM has Grown at 138.76%

-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)

Lowest at 10.54%

Here's what is working for Genomed SA
Operating Cash Flow
Highest at PLN 2.12 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (PLN MM)

Pre-Tax Profit
At PLN 0.24 MM has Grown at 139.77%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (PLN MM)

Net Profit
At PLN 0.24 MM has Grown at 138.76%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (PLN MM)

Cash and Eqv
Highest at PLN 10.03 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -47.05 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio
Highest at 11.3%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -195.5% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Genomed SA
Debtors Turnover Ratio
Lowest at 10.54%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."